Hematopoietic stem cells give rise to immature progenitors of each of the hematopoietic lineages, including megakaryocytes for which thrombopoietin (TPO) plays an important role in their development. Less is known about the role of TPO in the development of hematopoietic stem cells. Several approaches to evaluate stem cell function have been established; in some this population can be purified by sorting cells from bone marrow and cultured in the presence of one or more cytokines, monitoring for cell survival and proliferation. Using lineage depletion with antibodies, forward and side scatter in flow cytometry, and the capacity to extrude rhodamine and Hoechst dyes, we have found that in the absence of any growth factors stem cell populations die within 2-3 days. In the presence of interleukin (IL)-3 or steel factor (SF), most of these cells survive and many begin to proliferate. Surprisingly, TPO affects hematopoietic stem cells by supporting their survival, but when used alone, does not induce their proliferation. However, in combination with IL-3 or SF, TPO profoundly influences stem cell proliferation over that seen with IL-3 or SF alone. For example, after about 1 week of culture in IL-3 alone, only about 10% of the cells have entered the cell cycle; in the additional presence of TPO, 40% or 50% of the cells have begun to divide.
1 Similar data can be demonstrated for steel factor with TPO. Therefore, TPO has been shown to promote survival and induce proliferation of stem cells in the presence of other proliferative growth factors.
The role of TPO and its receptor in hematopoiesis has also been demonstrated in vivo by genetically eliminating the cMpl receptor in mice. 2 Using a competitive repopulation assay Mpl nullizygous mice display about one-seventh the number of hematopoietic stem cells as their wild-type counterparts, which appears to be insufficient to cause aplasia; other than severe thrombocytopenia, hematopoiesis is relatively normal. If the hematopoietic stem cell compartment is reduced, the hematopoietic progenitor cell compartment might also be compromised. In earlier work by Warren Alexander in Australia, the number of granulocyte-macrophage colony-forming cells in bone marrow was greatly reduced in Mpl knockout mice compared to normal. The same was true for BFU-E and mixed lineage colonies. in hematopoiesis. The prevalence of this disorder is approximately 50 cases in the United States, an equivalent number in Europe, and roughly half that number in Japan. The clinical presentation is isolated thrombocytopenia at birth, although some of these children are anemic as well. Nearly all such patients progress to aplastic anemia within the first decade of life. The marrow shows normal cellularity at the beginning of life with a very small number of megakaryocytes. 4 There are few survivors to adolescence unless stem cell transplantation can be performed. In the absence of this procedure, clinical care is usually supportive with transfusions.
Given the initial phenotype of very few small megakaryocytes and predominant thrombocytopenia, it was reasonable to assume that CAMT represents a disease either of TPO or of the TPO receptor, c-Mpl. However, immunoreactive TPO levels in these patients are uniformly high, a finding which does not necessarily exclude the possibility of an abnormal TPO, but in those patients in which it has been tested the circulating TPO appears to be fully active. Over the past several years it has become increasingly clear that the c-Mpl is defective in many patients with CAMT. Using PCR analysis of the c-Mpl gene in a patient with CAMT, Muraoka and colleagues 5 were the first to demonstrate a deficiency of Mpl-specific mRNA in a child with the disorder; gene sequencing demonstrated a mixed heterozygous pattern of c-Mpl gene mutations. More recently, Ballmaier and colleagues 4 demonstrated that in patients with CAMT TPO fails to potentiate P-selectin (CD62P) expression on the surface of platelets. If one assesses a number of proteins normally tyrosine-phosphorylated in response to TPO, such as c-Mpl, JAK, and several isoforms of the STAT proteins in the platelets of patients with CAMT, they are uniformly deficient in phosphorylation. Together, these results established that the defect in megakaryocytes and platelets of patients with CAMT is due to faulty signaling in response to TPO.
Of some interest, bone marrow culture studies in some patients with CAMT have been predictive of clinical course. At diagnosis most patients display reduced megakaryocyte colony growth, but relatively preserved myeloid and erythroid progentior cell numbers. However, with time, the numbers of all hematopoietic progenitors begins to fall, resulting in aplastic anemia. For example, in one reported patient the number of CFU-GM was relatively normal and the number of CFU-E was relatively well preserved at 1.5 years of age; however, 4 years later, all progenitors were deficient, hematopoiesis had failed, and the patient developed aplastic anemia. The importance of the Mpl receptor in stem cell biology helps to explain why CAMT might evolve into aplastic anemia. However, of some research interest, mice made genetically deficient in cMpl do not develop aplastic anemia, pointing to differences between human and mouse stem cell biology.
CAMT is a lethal disorder, with most patients succumbing by adolescence; at present the only therapy is allogeneic stem cell transplantation as CAMT is a monogenic disorder of a well-characterized gene, one could make a compelling case for developing a gene therapy approach for the disorder. Moreover, only a few receptors per cell are likely needed to provide cellular responses to TPO. Thus, if the Mpl promoter becomes available to drive tissue-specific expression, gene therapy could become a reality for CAMT, as is also becoming the case for severe combined immunodeficiency, the only present day successful example of gene therapy. In SCID due to ␥ c deficiency the corrected cells in patients with this disorder display a growth advantage, allowing the small fraction of transduced cells to expand.
To develop the concept of gene therapy for this condition, we have initiated preliminary experiments using the Mpl promoter to drive expression of the Mpl gene. The construct, employing a two kilobase region of the 5Ј flanking region of c-Mpl, is introduced into Mpl knockout mice as a transgene. Normal mice have a platelet count of about one million, and c-Mpl knockout mice a platelet count of about 100 000; Mpl −/− mice which carry a single copy of the transgene into the Mpl display platelet counts of about two million, twice as high as the normal mice. This does not appear to be related to over-expression of the Mpl gene itself. Thus, it appears that transgenic expression of Mpl is possible using a tissue-specific promoter. The same conditions apply to CAMT due to Mpl deficiency; correction of this receptor would provide the same selection advantage.
Despite this progress many questions remain about the role 
